跳至主要内容
临床试验/NCT00143364
NCT00143364已完成3 期

A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study With Follow-up Evaluating the Safety and Efficacy of Varenicline Tartrate ( CP-526,555) in Comparison to Zyban for Smoking Cessation

Pfizer14 个研究点 分布在 1 个国家目标入组 1,005 人开始时间: 2003年6月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
1,005
试验地点
14
主要终点
4 week Continuous Quit Rate ( 4 week CQR ) for Weeks 9 -12.

研究概览

简要总结

The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

排除标准

  • Subjects who have used bupropion (Zyban or Wellbutrin) previously.

结局指标

主要结局

4 week Continuous Quit Rate ( 4 week CQR ) for Weeks 9 -12.

次要结局

  • Continuous abstinence Weeks 9-52
  • Long-term Quit Rate Week 52
  • Continuous abstinence Weeks 9 -24
  • 7-day Point Prevalence Abstinence Weeks 12, 24, and 52
  • 4-week Point Prevalence Abstinence at Week 52
  • Minnesota Nicotine Withdrawal Scale
  • Brief Questionnaire of Smoking Urges
  • Smoking Effects Inventory
  • Change from baseline in bodyweight

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (14)

Loading locations...

相似试验